Antimicrobial resistance: what is pharma doing?
This article was originally published in Scrip
The UK recently saw the launch of a five-year antimicrobial resistance strategy, an initiative which will see it work with organizations across the globe to tackle a problem that almost everyone saw coming, but few have been able to do much about. While many initially expected the pharma industry to exploit the problem with innovative new antimicrobials, the reality has been that pharma companies have been forced to scale down their antimicrobial efforts or bow out of the area. Scrip spoke to Dr Catriona McMahon, AstraZeneca's director of UK medical and healthcare affairs, to find out why.